Be Biopharma
PrivateLast Round
Series C
Jan 15, 2025
Total Funding Raised
$356M
Company Overview
Be Biopharma operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series C round in January 2025.
Be Biopharma is a biotechnology company that develops engineered B cell medicines to treat genetic diseases, cancer, and autoimmune disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Be Biopharma Comparables
Compare Be Biopharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Immusoft | 85% | |
| Caribou Biosciences | 67% | |
| Fate Therapeutics, Inc. | 66% |
For institutional investors. Book with your work email.
Be Biopharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jan 15, 2025 | ||||
| Early Funding | Oct 22, 2024 | ||||
| Series B | Apr 14, 2022 | ||||
| Series A | Oct 23, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Be Biopharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series B, Series C, Early Funding, Series A |
| Dean Capital Investments Management | Series B |
| ARCH Venture Partners | Series C, Early Funding, Series B |
| Nextech Venture | Series C |
| Alta Administration | Series B |
| Atlas Venture | Series B, Series C, Early Funding, Series A |
| Nextech Invest | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 15, 2025
Therapeutic programs have advanced into human trials.
- Jan 15, 2025
$92M round completed.
For institutional investors. Book with your work email.
Be Biopharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Be Biopharma's valuation, stock price, and market status.
Is Be Biopharma a public or private company?
Be Biopharma is a private company.
What is the current stock price of Be Biopharma?
Be Biopharma is a private company, so its shares have no public market price. Caplight tracks Be Biopharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Be Biopharma worth (valuation)?
Valuation information for Be Biopharma is not publicly available.
Can I buy Be Biopharma stock?
Be Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Be Biopharma's last funding round?
Be Biopharma's most recent funding round was Series C on January 15, 2025.
Who are the main investors in Be Biopharma?
Key investors in Be Biopharma include RA Capital Management, ARCH Venture Partners, Atlas Venture.
Will Be Biopharma IPO soon?
No public IPO plans have been announced for Be Biopharma.
How can I track Be Biopharma secondary market activity?
Caplight tracks bids, offers, and trades in Be Biopharma's shares on secondary markets.